Back to top

pharmaceuticals: Archive

Zacks Equity Research

Regeneron (REGN) Dupixent Gets FDA Nod for Asthma in Children

Regeneron (REGN) and Sanofi's (SNY) Dupixent secures FDA approval to treat children aged 6-11 years with moderate to severe asthma.

REGNPositive Net Change SNYNegative Net Change RHHBYPositive Net Change NVONegative Net Change

Zacks Equity Research

Radius (RDUS) Up On Positive Data From Breast Cancer Study

Radius (RDUS) stock gains in response to positive results from a late-stage study evaluating breast cancer candidate, elacestrant.

REGNPositive Net Change LLYNegative Net Change AMGNNegative Net Change RDUSPositive Net Change

Indrajit Bandyopadhyay

FDA Approves JNJ & MRNA's COVID-19 Boosters & Mixing of Doses

The FDA authorizes booster doses of COVID-19 vaccines of JNJ and MRNA. It also authorizes a heterologous boosting option which will allow administration of booster dose of any available vaccine irrespective of the primary vaccination regimen.

JNJNegative Net Change PFENegative Net Change MRNAPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Will Eli Lilly (LLY) Surpass Q3 Earnings Expectations?

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) third-quarter sales.

REGNPositive Net Change PFENegative Net Change MRKNegative Net Change LLYNegative Net Change

Zacks Equity Research

Roche's (RHHBY) Tecentriq Gets FDA Nod for Another Indication (Revised)

Roche (RHHBY) immuno-oncology drug Tecentriq gets FDA approval for yet another indication of lung cancer.

AZNPositive Net Change RHHBYPositive Net Change BMYNegative Net Change MRKNegative Net Change

Sheraz Mian

Top Analyst Reports for Microsoft, Mastercard & Pfizer

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Mastercard Incorporated (MA), and Pfizer Inc. (PFE).

MSFTPositive Net Change CVXNegative Net Change MANegative Net Change PFENegative Net Change MRKNegative Net Change PEPNegative Net Change

Zacks Equity Research

Biotech Stock Roundup: BIIB's Q3 Earnings, REGN's COVID-19 Cocktail Update & More

Regulatory and pipeline updates from bigwigs like Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.

REGNPositive Net Change AZNPositive Net Change BIIBPositive Net Change GILDNegative Net Change AVIRNegative Net Change VALNPositive Net Change

Zacks Equity Research

Sage, Biogen Plan to File Zuranolone NDA for MDD in 2022

Sage (SAGE) and partner Biogen are looking to get approval for zuranolone as an oral treatment for major depressive disorder. They will start rolling submission of an NDA in early 2022 for the candidate.

BIIBPositive Net Change SAGEPositive Net Change VTGNNegative Net Change RLMDPositive Net Change

Mark Vickery

Markets Flat as Q3 Earnings Continue: VZ, ABT, TSLA & More

Markets are flat in this morning's pre-market Hump Day, following a nice string of daily outperformance across indexes.

NEEPositive Net Change ABTPositive Net Change VZNegative Net Change TSLAPositive Net Change

Zacks Equity Research

Roche (RHHBY) 9M21 Sales Grow on Strong COVID-19 Tests, View Up

Roche (RHHBY) posts an encouraging performance in the third quarter and the first nine months of 2021 driven by demand for coronavirus tests due to the Delta variant and recovery in pharma sales.

REGNPositive Net Change RHHBYPositive Net Change PFENegative Net Change ABBVNegative Net Change

Zacks Equity Research

Valneva (VALN) Reports Positive Data From COVID Vaccine Study

Valneva's (VALN) shares surge after its COVID vaccine demonstrates superiority over AstraZeneca's COVID vaccine in a phase III study.

AZNPositive Net Change PFENegative Net Change MRNAPositive Net Change VALNPositive Net Change

Zacks Equity Research

Esperion (ESPR) to Cut 40% Workforce, Revamp Cost Structure

Esperion (ESPR) is set reduce its workforce by 40% and start targeted program savings to reduce its operational expense and deliver consistent growth.

REGNPositive Net Change MRKNegative Net Change AMGNNegative Net Change ESPRNegative Net Change

Zacks Equity Research

J&J (JNJ) Beats on Q3 Earnings, Misses on Sales, Ups EPS View

J&J (JNJ) reports mixed third-quarter earnings. It beats estimates for earnings but misses the same for sales. It raises its earnings guidance range for the year.

JNJNegative Net Change PFENegative Net Change MRKNegative Net Change ABBVNegative Net Change

Zacks Equity Research

Gilead's (GILD) Biktarvy Gets FDA Nod for Pediatric Patients

Gilead (GILD) wins FDA approval for the label expansion of HIV treatment Biktarvy for the pediatric patient population.

REGNPositive Net Change GSKNegative Net Change MRKNegative Net Change GILDNegative Net Change

Zacks Equity Research

Pfizer (PFE) Gets CHMP Nod for JAK Inhibitor Abrocitinib

The CHMP recommends approving Pfizer (PFE) JAK inhibitors abrocitinib and Xeljanz for the treatment of atopic dermatitis and active ankylosing spondylitis, respectively.

PFENegative Net Change LLYNegative Net Change INCYNegative Net Change ABBVNegative Net Change

Zacks Equity Research

Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion

Gilead's (GILD) application for breast cancer drug gets positive opinion for approval from EMA's CHMP.

REGNPositive Net Change GSKNegative Net Change MRKNegative Net Change GILDNegative Net Change

Zacks Equity Research

Roche's (RHHBY) Tecentriq Gets FDA Nod for Another Indication

Roche (RHHBY) immuno-oncology drug Tecentriq gets FDA approval for yet another indication of lung cancer.

AZNPositive Net Change RHHBYPositive Net Change BMYNegative Net Change MRKNegative Net Change

Zacks Equity Research

J&J, Moderna COVID-19 Booster Jabs Near FDA Authorization

The FDA's Vaccines and Related Biological Products advisory committee recommends emergency use authorization for booster doses of J&J and Moderna's COVID-19 vaccines for use in certain adults.

JNJNegative Net Change PFENegative Net Change MRNAPositive Net Change BNTXPositive Net Change

Zacks Equity Research

J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector

J&J's (JNJ) Pharma segment is expected to have performed above market while market recovery might have benefited Medical Devices segment sales in the third quarter.

JNJNegative Net Change PFENegative Net Change MRKNegative Net Change LLYNegative Net Change

Zacks Equity Research

Prothena (PRTA) Riding High on Alzheimer's Disease Pipeline

Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.

BIIBPositive Net Change RHHBYPositive Net Change BMYNegative Net Change PRTAPositive Net Change

Zacks Equity Research

Exelixis (EXEL) Well Poised on Label Expansions of Caboemtyx

The going has been good for Exelixis (EXEL) on label expansions of its lead drug, Cabometyx. The pipeline progress has been encouraging as well.

RHHBYPositive Net Change BMYNegative Net Change BAYRYNegative Net Change EXELNegative Net Change

Zacks Equity Research

Incyte's (INCY) Going Gets Rough Despite Recent Approvals

Incyte (INCY) recent drug approvals fail to impress investors due to the FDA's warnings about increased risks of serious heart-related events, cancer, blood clots, and death for JAK inhibitors.

BMYNegative Net Change PFENegative Net Change INCYNegative Net Change ABBVNegative Net Change

Zacks Equity Research

Merck (MRK) Seeks Emergency Nod for Oral Antiviral COVID-19 Pill

Merck's (MRK) molnupiravir to be the first oral antiviral medicine for the treatment of COVID-19, if authorized by the FDA.

RHHBYPositive Net Change PFENegative Net Change MRKNegative Net Change AVIRNegative Net Change

Zacks Equity Research

Markets Await Economic and Earnings Data

Markets Await Economic and Earnings Data

JPMNegative Net Change NKEPositive Net Change PFENegative Net Change DALPositive Net Change COSTPositive Net Change MRNAPositive Net Change FDXNegative Net Change

Indrajit Bandyopadhyay

3 Small Biotech Stocks in Focus on World Arthritis Day

Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.

JNJNegative Net Change AMGNNegative Net Change ABBVNegative Net Change ALPNNegative Net Change IMABPositive Net Change BVSNegative Net Change